Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress

The downgrade besides comes aft Dr. Garcia and Jones Trading convened a cardinal sentiment person telephone connected November 5 to sermon the diligent who met Hy’s Law criteria. The treatment took spot anterior to the patient’s decease being announced the pursuing day.

Baird, noting the FDA’s clasp connected the NTLA-2001 attraction arsenic a large factor, besides lowered its terms people for the company’s shares to $9 portion maintaining a Neutral rating. Given the competitory situation successful the ATTR and HAE markets, the steadfast states that commercialized adoption of Intellia’s programs whitethorn beryllium hard adjacent if they summation regulatory approval.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is simply a biotech institution astatine the forefront of CRISPR-Cas9 gene-editing technology, processing cutting-edge treatments for some successful vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to dainty transthyretin amyloidosis, a illness that is presently incurable.

While we admit the imaginable of NTLA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.